RARE DISEASE
Schnitzler syndrome
Schnitzler syndrome
Schnitzler syndrome
Synonyms: Chronic urticaria with gammopathy, Chronic urticaria with macroglobulinemia
Synonyms: Chronic urticaria with gammopathy, Chronic urticaria with macroglobulinemia
Synonyms: Chronic urticaria with gammopathy, Chronic urticaria with macroglobulinemia
Drug discovery
2
drugs
With orphan designations
Overview
Schnitzler syndrome is a rare autoinflammatory disorder characterized by chronic nonpruritic urticaria, monoclonal gammopathy (typically IgMκ), and systemic inflammation. Key features include recurrent fever, arthralgia, bone pain, fatigue, and elevated inflammatory markers. Diagnosis is often delayed (median 5 years) due to under-recognition. Pathogenesis involves IL-1 dysregulation, making IL-1 inhibitors (e.g., anakinra) highly effective. Long-term risks include AA amyloidosis and lymphoproliferative disorders (e.g., lymphoma) in 8–20% of cases [1][2][6][12].
Burden
Morbidity: Chronic symptoms (rash, fever, pain) severely impact quality of life; untreated cases risk AA amyloidosis [4][9][12].
Diagnostic delay: Median 5 years, leading to prolonged suffering and irreversible complications (e.g., joint damage) [1][8][9].
Progression: 8–20% develop lymphoproliferative disorders; median survival >12.8 years with treatment [1][6][12].
Therapies
First-line: IL-1 blockade (anakinra) induces rapid, sustained symptom remission [1][5][11].
Alternatives: Colchicine for mild cases, IL-1β inhibitors (canakinumab), or Bruton tyrosine kinase inhibitors (ibrutinib) [3][7][14].
Avoid corticosteroids/immunosuppressants due to limited efficacy and side effects [5][15].
Categories: rare systemic and rheumatological diseases
Research Papers
198 drug discovery papers about Schnitzler syndrome, with 1 first-in-class and 1 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
198 drug discovery papers about Schnitzler syndrome, with 1 first-in-class and 1 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
2026-05-28 | Monoclonal gammopathy–associated autoinflammation: A systematic review and meta-analysis of Schnitzler syndrome.
e19579 Background: Schnitzler syndrome is a rare, underdiagnosed disorder that usually presents with late-onset systemic inflammation and monoclonal gammopathy. Key clinical findings include chronic urticarial rash, fever, bone pain, and lymphadenopathy. Given that most data regarding this rare disease are derived from small observational studies, this study aims to systematically characterize the demographic, clinical, laboratory, and treatment outcomes of patients with Schnitzler syndrome. Methods: A thorough literature search of the PubMed, Scopus, and Web of Science databases was performed in September 2025. Data on medical history, presentations, complications, diagnostics, treatment patterns, and outcomes were obtained. Results: This pooled analysis includes 187 articles reporting 243 individual cases of Schnitzler syndrome over the years 1989–2025. The mean patient age was 57.4 years ±12.2 with a male-to-female ratio of 1.32:1, indicating a slight male predominance. The most frequently reported manifestations were chronic urticarial rash (226/243, 93.0%), fever (194/243, 79.8%), and arthralgia (145/243, 59.7%), with lymphoid involvement mainly manifesting as lymphadenopathy (63/243, 25.9%); progression to lymphoproliferative disorders was rare (15/243, 6.2%). Most patients presented with an IgM gammopathy (193/243, 79.4%), confirming IgM as the predominant class. In a smaller subset, IgG (26/243, 10.7%) and IgA (3/243, 1.2%) gammopathy was present. Regarding light chain type, kappa predominated (162/243, 66.7%), with fewer cases of lambda (22/243, 9.1%). When stratified by immunoglobulin class, age differed significantly between patients with IgM and IgG gammopathy (58.5 vs 50.8 years, p = 0.015). IL-1 inhibitors were frequently used, with 124/243 patients receiving this therapy (51.0%). Corticosteroids of various formulations were administered in 154/243 patients (63.4%). Treatment response was favorable in most patients, with 126/243 achieving a complete clinical response (51.9%) and 47/243 a partial response (19.3%). Sixteen patients showed no response (6.6%). On multivariate analysis, IL-1 inhibitor use was independently associated with higher odds of complete response (OR 7.89; 95% CI 1.70–36.65). In the minority of patients who relapsed after an initial response to IL-1 inhibitors due to treatment discontinuation or tapering, the addition of corticosteroids restored the response. Conclusions: Schnitzler syndrome is a rare autoinflammatory condition predominantly affecting older males, characterized by chronic urticaria, fever, and IgM kappa gammopathy. While IL-1 inhibitors and corticosteroids offer high rates of clinical response, the frequent relapse upon tapering underscores the need for long-term maintenance. Studies are needed to explore if anti-plasma cell therapy would decrease relapse and induce long-term remission.
2026-05-22 | Cutaneous diseases caused by monoclonal immunoglobulin and/or free light chains (monoclonal gammopathy of cutaneous significance).
Monoclonal immunoglobulin (M-Ig) and/or free light chains (FLC) can cause a wide range of organ and tissue damage. The most common are various forms of nephropathies, for which the term monoclonal gammopathy of renal significance was created, and a morphological classification was proposed by the "International Kidney and Monoclonal Gammopathy Research Group." Another large group consists of clinical entities where, among other things, various forms of skin damage occur. For these, the group designation monoclonal gammopathy of cutaneous significance was created. Although the etiopathogenesis is hematologic, the symptoms lead patients with this form of monoclonal gammopathy-related damage to dermatology clinics. Dermatological publications from the last 5 years distinguish diseases with a clearly expressed etiopathogenetic connection to monoclonal gammopathy, defining a total of 12, and then mention other diseases in which the etiopathogenetic relationship is less clear. The group of skin diseases with a clearly demonstrated connection to monoclonal gammopathy includes: AL amyloidosis of the skin, cutaneous macroglobulinemia, skin changes in POEMS syndrome, scleromyxedema, scleroderma, diffuse normolipidemic xanthomas, necrobiotic xanthogranuloma, urticaria in Schnitzler syndrome, telangiectasia in TEMPI syndrome, localized erythema in AESOP syndrome, cryoglobulinemic skin changes, cutis laxa (loose skin). Among the diseases with a less clear connection to monoclonal immunoglobulin, we mention IgA pemphigus. The text provides brief descriptions supplemented with imaging documentation of cases we have encountered over the past 35 years. If a dermatologist encounters the mentioned diseases, they should examine M-Ig and FLC, and in the case of a positive finding, consult with a hematologist regarding the possibility of targeted therapy.
2026-04-11 | The Role of Corticosteroid Therapy in Schnitzler Syndrome: A Case Report
Background: Urticaria is a common inflammatory mucocutaneous syndrome with multiple etiologies. When recalcitrant to standard antihistamine therapy, a systematic diagnostic workup is essential to identify rare underlying systemic conditions such as Schnitzler Syndrome. Case Presentation: We report the case of a 41-year-old woman with a background of chronic asthma, fibromyalgia, degenerative retinopathy, and nasal polyposis, who presented with an 8-month history of recalcitrant urticarial eruption. Despite sequential trials of multiple antihistamine regimens including cetirizine, hydroxyzine, loratadine, levocetirizine, desloratadine, montelukast, and bilastine at standard and quadruple doses no clinical improvement was observed. Extensive etiological workup excluded common chronic urticaria, drug-induced, infectious, inducible, and autoimmune causes, as well as urticarial vasculitis, Adult-onset Still's disease, systemic lupus erythematosus, and Cryopyrin-Associated Periodic Syndromes (CAPS). Serum protein electrophoresis revealed a monoclonal peak in the gamma-globulin zone, confirmed by immunofixation as monoclonal IgG elevation, establishing the diagnosis of Schnitzler Syndrome. Treatment and Outcome: The patient was initiated on corticosteroid therapy with prednisolone 40 mg/day for 3 months, resulting in marked clinical improvement. Conclusion: This case highlights the importance of a thorough diagnostic approach in chronic recalcitrant urticaria. While antihistamines remain the first-line treatment, corticosteroid therapy may play a critical role in antihistamine-refractory forms, particularly in the context of Schnitzler Syndrome. Clinicians should consider monoclonal gammopathy screening in patients with persistent urticaria unresponsive to standard therapy.
2026-04-06 | Bruton protein-tyrosine kinase (BTK) FDA-approved small molecule inhibitors used for the management of neoplastic and inflammatory disorders.
The Bruton nonreceptor protein-tyrosine kinase (BTK) plays a central role in B cell antigen receptor signaling. Following B cell receptor activation, the Src protein kinase Lyn and the spleen protein kinase (Syk) activate BTK. It then mediates the phosphorylation and activation of phospholipase Cγ2 (PLCγ2). The Ras/RAF/MEK/ERK and NF-κB pathways are downstream of PLCγ2. These signaling modules participate in the affinity maturation of antibody-producing B cells by somatic hypermutation. The absence of BTK results in X-linked agammaglobulinemia. BTK contains an amino-terminal PH (pleckstrin homology) domain that interacts with phosphatidyl inositol trisphosphate within the plasma membrane to promote its membrane association. This is followed by a TEC homology segment, an SH3 and SH2 domain, and finally a carboxyterminal protein kinase domain. Aberrant B cell receptor signaling occurs in several B cell neoplasms including follicular lymphoma (treated with zanubrutinib, a BTK inhibitor), mantle cell lymphoma (acalabrutinib, pirtobrutinib, zanubrutinib), marginal zone lymphoma (zanubrutinib), chronic lymphocytic leukemia and small lymphocytic lymphoma (ibrutinib, acalabrutinib, zanubrutinib, pirtobrutinib), and Waldenström macroglobulinemia (ibrutinib, zanubrutinib). Chronic spontaneous urticaria and chronic immune thrombocytopenia are driven by B cell dysfunction. The former is treated with remibrutinib and the latter is treated with rilzabrutinib, both of which inhibit BTK. Four drugs (ibrutinib, acalabrutinib, zanubrutinib, remibrutinib) form an irreversible covalent bond and rilzabrutinib forms a reversible covalent bond with BTK Cys481. Pirtobrutinib fails to form a covalent bond and is a reversible BTK inhibitor. The FDA-approvals of rilzabrutinib and remibrutinib (2025) represent the first nononcologic authorizations for BTK antagonists.
2026-01-22 | [No mistakes with Schnitzler syndrome].
Schnitzler syndrome is a rare autoinflammatory disease that primarily manifests in adulthood. In cases presenting with chronic urticaria and paraproteinemia, Schnitzler syndrome should be considered in the differential diagnosis, and the Strassburg criteria should be applied to establish the diagnosis. IL-1 inhibitors have proven to be an effective long-term treatment for Schnitzler syndrome. Patients should be moni-tored for the potential development of lymphoproliferative disorders and/or amyloidosis.
2026-05-28 | Monoclonal gammopathy–associated autoinflammation: A systematic review and meta-analysis of Schnitzler syndrome.
e19579 Background: Schnitzler syndrome is a rare, underdiagnosed disorder that usually presents with late-onset systemic inflammation and monoclonal gammopathy. Key clinical findings include chronic urticarial rash, fever, bone pain, and lymphadenopathy. Given that most data regarding this rare disease are derived from small observational studies, this study aims to systematically characterize the demographic, clinical, laboratory, and treatment outcomes of patients with Schnitzler syndrome. Methods: A thorough literature search of the PubMed, Scopus, and Web of Science databases was performed in September 2025. Data on medical history, presentations, complications, diagnostics, treatment patterns, and outcomes were obtained. Results: This pooled analysis includes 187 articles reporting 243 individual cases of Schnitzler syndrome over the years 1989–2025. The mean patient age was 57.4 years ±12.2 with a male-to-female ratio of 1.32:1, indicating a slight male predominance. The most frequently reported manifestations were chronic urticarial rash (226/243, 93.0%), fever (194/243, 79.8%), and arthralgia (145/243, 59.7%), with lymphoid involvement mainly manifesting as lymphadenopathy (63/243, 25.9%); progression to lymphoproliferative disorders was rare (15/243, 6.2%). Most patients presented with an IgM gammopathy (193/243, 79.4%), confirming IgM as the predominant class. In a smaller subset, IgG (26/243, 10.7%) and IgA (3/243, 1.2%) gammopathy was present. Regarding light chain type, kappa predominated (162/243, 66.7%), with fewer cases of lambda (22/243, 9.1%). When stratified by immunoglobulin class, age differed significantly between patients with IgM and IgG gammopathy (58.5 vs 50.8 years, p = 0.015). IL-1 inhibitors were frequently used, with 124/243 patients receiving this therapy (51.0%). Corticosteroids of various formulations were administered in 154/243 patients (63.4%). Treatment response was favorable in most patients, with 126/243 achieving a complete clinical response (51.9%) and 47/243 a partial response (19.3%). Sixteen patients showed no response (6.6%). On multivariate analysis, IL-1 inhibitor use was independently associated with higher odds of complete response (OR 7.89; 95% CI 1.70–36.65). In the minority of patients who relapsed after an initial response to IL-1 inhibitors due to treatment discontinuation or tapering, the addition of corticosteroids restored the response. Conclusions: Schnitzler syndrome is a rare autoinflammatory condition predominantly affecting older males, characterized by chronic urticaria, fever, and IgM kappa gammopathy. While IL-1 inhibitors and corticosteroids offer high rates of clinical response, the frequent relapse upon tapering underscores the need for long-term maintenance. Studies are needed to explore if anti-plasma cell therapy would decrease relapse and induce long-term remission.
2026-05-22 | Cutaneous diseases caused by monoclonal immunoglobulin and/or free light chains (monoclonal gammopathy of cutaneous significance).
Monoclonal immunoglobulin (M-Ig) and/or free light chains (FLC) can cause a wide range of organ and tissue damage. The most common are various forms of nephropathies, for which the term monoclonal gammopathy of renal significance was created, and a morphological classification was proposed by the "International Kidney and Monoclonal Gammopathy Research Group." Another large group consists of clinical entities where, among other things, various forms of skin damage occur. For these, the group designation monoclonal gammopathy of cutaneous significance was created. Although the etiopathogenesis is hematologic, the symptoms lead patients with this form of monoclonal gammopathy-related damage to dermatology clinics. Dermatological publications from the last 5 years distinguish diseases with a clearly expressed etiopathogenetic connection to monoclonal gammopathy, defining a total of 12, and then mention other diseases in which the etiopathogenetic relationship is less clear. The group of skin diseases with a clearly demonstrated connection to monoclonal gammopathy includes: AL amyloidosis of the skin, cutaneous macroglobulinemia, skin changes in POEMS syndrome, scleromyxedema, scleroderma, diffuse normolipidemic xanthomas, necrobiotic xanthogranuloma, urticaria in Schnitzler syndrome, telangiectasia in TEMPI syndrome, localized erythema in AESOP syndrome, cryoglobulinemic skin changes, cutis laxa (loose skin). Among the diseases with a less clear connection to monoclonal immunoglobulin, we mention IgA pemphigus. The text provides brief descriptions supplemented with imaging documentation of cases we have encountered over the past 35 years. If a dermatologist encounters the mentioned diseases, they should examine M-Ig and FLC, and in the case of a positive finding, consult with a hematologist regarding the possibility of targeted therapy.
2026-04-11 | The Role of Corticosteroid Therapy in Schnitzler Syndrome: A Case Report
Background: Urticaria is a common inflammatory mucocutaneous syndrome with multiple etiologies. When recalcitrant to standard antihistamine therapy, a systematic diagnostic workup is essential to identify rare underlying systemic conditions such as Schnitzler Syndrome. Case Presentation: We report the case of a 41-year-old woman with a background of chronic asthma, fibromyalgia, degenerative retinopathy, and nasal polyposis, who presented with an 8-month history of recalcitrant urticarial eruption. Despite sequential trials of multiple antihistamine regimens including cetirizine, hydroxyzine, loratadine, levocetirizine, desloratadine, montelukast, and bilastine at standard and quadruple doses no clinical improvement was observed. Extensive etiological workup excluded common chronic urticaria, drug-induced, infectious, inducible, and autoimmune causes, as well as urticarial vasculitis, Adult-onset Still's disease, systemic lupus erythematosus, and Cryopyrin-Associated Periodic Syndromes (CAPS). Serum protein electrophoresis revealed a monoclonal peak in the gamma-globulin zone, confirmed by immunofixation as monoclonal IgG elevation, establishing the diagnosis of Schnitzler Syndrome. Treatment and Outcome: The patient was initiated on corticosteroid therapy with prednisolone 40 mg/day for 3 months, resulting in marked clinical improvement. Conclusion: This case highlights the importance of a thorough diagnostic approach in chronic recalcitrant urticaria. While antihistamines remain the first-line treatment, corticosteroid therapy may play a critical role in antihistamine-refractory forms, particularly in the context of Schnitzler Syndrome. Clinicians should consider monoclonal gammopathy screening in patients with persistent urticaria unresponsive to standard therapy.
2026-04-06 | Bruton protein-tyrosine kinase (BTK) FDA-approved small molecule inhibitors used for the management of neoplastic and inflammatory disorders.
The Bruton nonreceptor protein-tyrosine kinase (BTK) plays a central role in B cell antigen receptor signaling. Following B cell receptor activation, the Src protein kinase Lyn and the spleen protein kinase (Syk) activate BTK. It then mediates the phosphorylation and activation of phospholipase Cγ2 (PLCγ2). The Ras/RAF/MEK/ERK and NF-κB pathways are downstream of PLCγ2. These signaling modules participate in the affinity maturation of antibody-producing B cells by somatic hypermutation. The absence of BTK results in X-linked agammaglobulinemia. BTK contains an amino-terminal PH (pleckstrin homology) domain that interacts with phosphatidyl inositol trisphosphate within the plasma membrane to promote its membrane association. This is followed by a TEC homology segment, an SH3 and SH2 domain, and finally a carboxyterminal protein kinase domain. Aberrant B cell receptor signaling occurs in several B cell neoplasms including follicular lymphoma (treated with zanubrutinib, a BTK inhibitor), mantle cell lymphoma (acalabrutinib, pirtobrutinib, zanubrutinib), marginal zone lymphoma (zanubrutinib), chronic lymphocytic leukemia and small lymphocytic lymphoma (ibrutinib, acalabrutinib, zanubrutinib, pirtobrutinib), and Waldenström macroglobulinemia (ibrutinib, zanubrutinib). Chronic spontaneous urticaria and chronic immune thrombocytopenia are driven by B cell dysfunction. The former is treated with remibrutinib and the latter is treated with rilzabrutinib, both of which inhibit BTK. Four drugs (ibrutinib, acalabrutinib, zanubrutinib, remibrutinib) form an irreversible covalent bond and rilzabrutinib forms a reversible covalent bond with BTK Cys481. Pirtobrutinib fails to form a covalent bond and is a reversible BTK inhibitor. The FDA-approvals of rilzabrutinib and remibrutinib (2025) represent the first nononcologic authorizations for BTK antagonists.
2026-01-22 | [No mistakes with Schnitzler syndrome].
Schnitzler syndrome is a rare autoinflammatory disease that primarily manifests in adulthood. In cases presenting with chronic urticaria and paraproteinemia, Schnitzler syndrome should be considered in the differential diagnosis, and the Strassburg criteria should be applied to establish the diagnosis. IL-1 inhibitors have proven to be an effective long-term treatment for Schnitzler syndrome. Patients should be moni-tored for the potential development of lymphoproliferative disorders and/or amyloidosis.
Access all drug discovery papers and probability of success in trials forecasts:
Access all drug discovery papers and probability of success in trials forecasts:
Drug Discovery Landscape
2 orphan drug designations for Schnitzler syndrome.
2 orphan drug designations for Schnitzler syndrome.
Drug | Therapy type | Regulator | Orphan designation | Approval | Sponsor |
|---|---|---|---|---|---|
heterodimeric fusion protein that binds to IL-1 beta consisting of human extracellular domain of IL1 receptor and a mutant Fc fragment of human IgG1 and part of human IL1 receptor accessory protein | proteins | FDA | 2018-10-15 | — | R-Pharm Overseas |
Gevokizumab | antibodies | EMA | 2014-08-22 | — | Xoma UK Limited |
Let's accelerate rare disease drug discovery
Let's accelerate drug discovery
Get access to Explority AI's forecasts to outperform average preclinical success rates. Whether you're expanding your R&D pipeline, evaluating a partnership, or simply have a question — we'd love to hear from you.